Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Observation × Lymphoid × Clear all

Phase

Status

Completed 7 Recruiting 5 Not yet recruiting 3 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4 Gastrointestinal 4 Breast 3 Sarcoma 2 Gynecologic 2 Thoracic 1 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Endocrine 1

Conditions

Leukemia, B-Cell 1

Interventions

Rituximab 194 Cyclophosphamide 125 fludarabine 58 Vincristine 56 Methotrexate 56 Doxorubicin 47 Etoposide 44 Cytarabine 43 fludarabine phosphate 42 Prednisone 40 Lenalidomide 40 Filgrastim 39 Dexamethasone 39 Bortezomib 30 Whole-Body Irradiation 29 Radiotherapy 28 Gemcitabine 28 Mycophenolic Acid 26 Melphalan 26 Granulocyte Colony-Stimulating Factor 26 Bendamustine Hydrochloride 26 Calcium Dobesilate 25 Antilymphocyte Serum 25 obinutuzumab 24 Alemtuzumab 24 venetoclax 23 ibrutinib 23 Tacrolimus 22 Busulfan 22 Cyclosporine 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01039376 2019-07-30

PROLONG

Novartis

Phase 3 Terminated

480 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡